Caplacizumab-yhdp (Cablivi®)

Cablivi (caplacizumab-yhdp) is covered for adults (≥18) with acquired thrombotic thrombocytopenic purpura (aTTP) only when used in combination with plasma exchange and immunosuppressive therapy; use outside these parameters is not covered. Approval requires inpatient initiation with plasma exchange, prescription by or in consultation with a hematologist, concurrent use of at least one immunosuppressive agent, adherence to dosing (11 mg IV ≥15 minutes before first plasma exchange then 11 mg SC after that exchange and 11 mg SC daily after subsequent exchanges), a limit of 60 doses after the last plasma exchange, prior-exposure limits (no more than two recurrences on Cablivi), and approval is limited to 2 months.

"Medication administration records documenting Cablivi dosing consistent with recommended schedule (including first-day IV bolus ≥15 minutes prior to plasma exchange, same-day SC after plasma exchan..."